Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) Enterprise Value (2022 - 2026)

TriSalus Life Sciences has reported Enterprise Value over the past 5 years, most recently at -$56.6 million for Q1 2026.

  • For Q1 2026, Enterprise Value fell 335.02% year-over-year to -$56.6 million; the TTM value through Mar 2026 reached -$56.6 million, down 335.02%, while the annual FY2025 figure was -$20.4 million, 139.75% down from the prior year.
  • Enterprise Value for Q1 2026 was -$56.6 million at TriSalus Life Sciences, down from -$20.4 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$69182.0 in Q2 2022 and troughed at -$56.6 million in Q1 2026.
  • A 5-year average of -$13.9 million and a median of -$11.5 million in 2023 define the central range for Enterprise Value.
  • On a YoY basis, Enterprise Value climbed as much as 47.21% in 2024 and fell as far as 15750.93% in 2024.
  • Year by year, Enterprise Value stood at -$9.4 million in 2022, then decreased by 25.1% to -$11.8 million in 2023, then grew by 27.61% to -$8.5 million in 2024, then tumbled by 139.75% to -$20.4 million in 2025, then tumbled by 176.69% to -$56.6 million in 2026.
  • Business Quant data shows Enterprise Value for TLSI at -$56.6 million in Q1 2026, -$20.4 million in Q4 2025, and -$22.7 million in Q3 2025.